Evidence map›Paper›PMID 20871837›Full record

ArticleToxins2010

Escherichia coli Subtilase Cytotoxin.

Adrienne W Paton, James C Paton

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 56 citations in OpenAlex.

  1. Cholera toxin as a model ABArchives of toxicology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. The diverse landscape of AB5-type toxins.Engineering microbiology · 2023
    Review
  6. Article
  7. Prevalence and Implications of Shiga Toxin-ProducingPathogens (Basel, Switzerland) · 2022
    Review
  8. EnterohemorrhagicInternational journal of molecular sciences · 2022
    Review
  9. ABToxins · 2022
    Review
  10. The evolutionary diversification of theFrontiers in microbiology · 2022
    Article
  11. Investigation of the Genes Involved in the Outbreaks ofAntibiotics (Basel, Switzerland) · 2021
    Article
  12. Article
  13. Variants ofToxins · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Adrienne W PatonResearch Centre for Infectious Diseases, School of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA 5005, Australia.
James C Paton
University of Adelaide · AU

Funding

Characterization of a novel AB5 cytotoxinR01AI068715 · NIAID · UNIVERSITY OF ADELAIDE · PI PATON, ADRIENNE W · 2007 to 2011
$1.3M
NIAID NIH HHS R01 AI068715
6 · The paper itself

Abstract

Subtilase cytotoxin (SubAB) is the prototype of a new AB(5) toxin family produced by a subset of Shiga toxigenic Escherichia coli (STEC) strains. Its A subunit is a subtilase-like serine protease and cytotoxicity for eukaryotic cells is due to a highly specific, single-site cleavage of BiP/GRP78, an essential Hsp70 family chaperone located in the endoplasmic reticulum (ER). This cleavage triggers a severe and unresolved ER stress response, ultimately triggering apoptosis. The B subunit has specificity for glycans terminating in the sialic acid N-glycolylneuraminic acid. Although its actual role in human disease pathogenesis is yet to be established, SubAB is lethal for mice and induces pathological features overlapping those seen in the haemolytic uraemic syndrome, a life-threatening complication of STEC infection. The toxin is also proving to be a useful tool for probing the role of BiP and ER stress in a variety of cellular functions.

Identifiers

PMID20871837
PMCPMC2943149
OpenAlexW1986255967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.